Releases

The company is pleased to announce the success of a Phase 2a clinical trial of oral anti-CD3 Immunotherapy in subjects suffering from chronic Hepatitis C

October 02, 2012

Read More

The company is pleased to announce that it has completed enrollment of its Phase 2a clinical trial of Oral anti-CD3 Immunotherapy in Poland and Austria in subjects suffering from chronic Hepatitis C.

February 26, 2012

Read More

The company is pleased to announce that it has received approval in principle from the Israel Office of the Chief Scientist to receive research grants totaling 3.5 million NIS.

January 16, 2012

Read More

The company announces that until 19 December 2011, it has not received and does not expect notification from GSK of its exercising its option to in-license proteins from the company.

December 20, 2011

Read More

The company is pleased to announced the continuation of its Joint Research and Option for License Agreement with Novartis until 18 April 2012.

November 20, 2011

Read More

NasVax is pleased to announce that it has initiated its Phase 2a clinical trial of Oral anti-CD3 Immunotherapy in subjects suffering from chronic Hepatitis C

October 27, 2011

Read More

NasVax is updating that GSK has made an additional and final payment as part of its Collaborative Research and Option Agreement for pneumococcal protein vaccine.

September 20, 2011

Read More

The company is pleased to announce the appointment of Mr. Guy Yachin as the company’s CEO affective 1 October 2011.

September 18, 2011

Read More

NasVax is pleased to announce that it has received an additional approval to conduct a Phase 2a clinical trial of Oral anti-CD3 Immunotherapy in subjects suffering from chronic Hepatitis C.

August 28, 2011

Read More

NasVax is pleased to announce that it has received approval to conduct a Phase 2a clinical trial of Oral anti-CD3 Immunotherapy in subjects suffering from chronic Hepatitis C.

August 07, 2011

Read More

NasVax Announces Extension of its Research Collaboration Agreement with Novartis

April 20, 2011

Read More

NasVax announces the success of a Phase 2a clinical trial

March 21, 2011

Read More

NasVax Announces the Success of a Phase 2a Clinical Trial of a New Oral Immunotherapy for Fatty Liver Disease

March 21, 2011

Read More

NasVax (Protea) receives approval in principle from the Office of the Chief Scientist for its grant in support of the group-common pneumococcal vaccine program

December 26, 2010

Read More

NasVax receives approval in principle from the Office of the Chief Scientist for its grant in support of the oral anti-CD3 immunotherapy program

December 23, 2010

Read More

NasVax receives receipt of patent allowance in the United States for oral anti-CD3 technology

October 05, 2010

Read More

NasVax receives approval from the US Patent & Trademark Office for the BBS1 Technology

September 20, 2010

Read More

NasVax starts Phase 2a clinical trial for oral aCD3 immunotherapy in NASH subjects

September 12, 2010

Read More

NasVax signes an agreement with Centocor Ortho for oral anti-CD3 immunotherapy

August 24, 2010

Read More

NasVax receives full approval to start Phase 2a clinical study for oral anti-CD3 immunotherapy in subjects with NASH ("fatty liver")

August 22, 2010

Read More

NasVax receives approval from the US Patent & Trademark Office for the Vaxisome Technology

August 10, 2010

Read More

NasVax Clinical Trial Phase II Results

March 28, 2010

Read More

NasVax Licenses with Hadasit Medical Research

March 28, 2010

Read More

NasVax Negotiates for License on a new Immunotherapeutic Technology

March 16, 2010

Read More

NasVax Signs a Joint Research and Option for License Agreement with Novartis

February 21, 2010

Read More

NasVax reports positive results for swine flu vaccine

December 20, 2009

Read More

NasVax reports successful initial trial of swine flu vaccine

October 12, 2009

Read More

NasVax (Protea) receives approval in-principal for research grant

September 03, 2009

Read More

NasVax: Closing Share Purchase Agreement of Protea Vaccine Technologies

July 12, 2009

Read More

NasVax (Protea) signs an exclusive Research and License Option Agreement with GSK for a universal protein-based Pneumococcal vaccine

June 16, 2009

Read More

NasVax commences a Phase I/ IIa dose-optimization clinical study of VaxiSomeTM-adjuvanted Influenza Vaccine. The company presents positive results for VaxiSome in its initial clinical study with intramuscular dosing

October 30, 2008

Read More

Positive preliminary results of a phase 1/2a clinical trial and further clinical trials

August 10, 2008

Read More

NasVax signed a Partnership Agreement with SciGen Ltd. for developing & marketing an Improved Hepatitis B Vaccine

December 09, 2007

Read More

Dr. Ronald Ellis, appointed Senior Vice President & Chief Technical Officer of Israeli Biotechnology Company, NasVax

August 16, 2007

Read More

NasVax receives Ministry of Health Approval for a Phase 1/2a Clinical Study for Improved Flu Vaccine

August 16, 2007

Read More

Erez Chimovits has been appointed CEO NasVax; Dr. Itzik Goldwaser has been appointed President of the Company

March 18, 2007

Read More

NasVax announces Successful Completion of another Pre-Clinical Trial

March 13, 2007

Read More